文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

转移性黑色素瘤联合免疫治疗因irAE停药后重启抗PD-1的安全性

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
PubMed 文献 · Ann Oncol · 2018-01-01

多中心研究评估转移性黑色素瘤患者因CTLA-4/PD-1联合阻断相关irAE停药后重启抗PD-1的安全性。重启时仍在用激素者毒性发生率更高(55% vs 31%,P=0.03),联合所致结肠炎复发率较低(6% vs 28%,P=0.01)。

要点

  • 因严重irAE停联合治疗后重启抗PD-1,复发irAE率18%,新发毒性率21%。
  • 重启时仍在用激素者毒性发生率更高(55% vs 31%,P=0.03)。
  • 联合所致结肠炎复发率低于其他irAE(6% vs 28%,P=0.01),部分患者可耐受重启。

核心结论

  • 因CTLA-4/PD-1联合阻断严重irAE停药者重启抗PD-1后复发或新发毒性率相对较高,但许多患者尤其联合所致结肠炎者可良好耐受重启,可在选定患者中考虑该策略。

主要发现

  • 全部重启抗PD-1,14例(18%)在中位14天后复发irAE(6例1-2级、7例3-4级、1例5级Steven-Johnson综合征)。
  • 结肠炎较其他irAE更少复发(6% vs 28%,P=0.01)。
  • 另17例(21%)出现临床显著但不同的毒性(11例1-2级、6例3-4级)。
  • 激素减量持续时间、初始irAE严重程度及额外免疫抑制使用未预测重启毒性,但重启抗PD-1时仍在激素治疗者毒性发生率更高(55% vs 31%,P=0.03)。

临床怎么用

  • 因联合免疫治疗严重irAE停药后,可在选定患者中考虑重启抗PD-1,尤其联合所致结肠炎者耐受较好。
  • 重启抗PD-1时仍在用激素者毒性发生率更高(55% vs 31%,P=0.03)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) blockade induces high rates of immune-related adverse events (irAEs). The safety of resuming anti-PD-1 in patients who discontinue combination therapy due to irAEs is not known. PATIENTS AND METHODS: We assessed patients who experienced clinically significant irAEs from combined CTLA-4 and PD-1 blockade leading to treatment discontinuation at four academic centers. We assessed the safety of resuming anti-PD-1 in terms of recurrent and distinct irAEs. RESULTS: Eighty patients discontinued combination therapy due to irAEs, including colitis (41%), hepatitis (36%), and pneumonitis (4%). Of these, 96% received corticosteroids and 21% received additional immunosuppression (e.g. infliximab). All were rechallenged with anti-PD-1, and 14 (18%) had recurrent irAEs at a median of 14 days after therapy resumption (six grade 1-2, seven grade 3-4, and one grade 5 Steven-Johnson Syndrome). Colitis was less likely to recur than other irAEs (6% versus 28%, P = 0.01). Clinically significant but distinct toxicities occurred in an additional 17 (21%) patients (11 grade 1-2 and 6 grade 3-4). Duration of steroid taper, severity of initial irAEs and use of additional immunosuppressants did not predict for toxicity on rechallenge, although patients remaining on steroid therapy at anti-PD-1 resumption had higher rates of toxicities (55% versus 31%, P = 0.03). CONCLUSIONS: Patients who discontinued CTLA-4/PD-1 blockade for severe irAEs had relatively high rates of recurrent or distinct toxicities with anti-PD-1 resumption. However, many patients, particularly with combination-induced colitis, tolerated anti-PD-1 rechallenge well, and this approach can be considered in selected patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018. PMID: 29045547. doi:10.1093/annonc/mdx642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。